171.68 +0.38 (0.22%)
Pre-Market: 4:43AM EDT
|Bid||168.72 x 900|
|Ask||175.05 x 800|
|Day's Range||168.59 - 172.05|
|52 Week Range||166.30 - 210.19|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||13.66|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||5.80 (3.23%)|
|1y Target Est||206.10|
Amgen announced Wednesday an agreement to buy Copenhagen-based Nuevolution for $167 million. The U.S. company announced a recommended public cash offer to Nuevolution shareholders to tender their shares for 32.5 Swedish kronas ($3.37) each in cash. The target company's board has unanimously recommended Amgen's cash tender offer to its shareholders.
Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns . Amgen's cash offer of 32.5 ...
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the United States should refer to the section entitled "Important Information to U.S. Shareholders" at the end of this press release. Amgen Inc. ("Amgen") (AMGN) today announces a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer").
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.
It's been a rather green day on Wall Street as all three major indexes are positive. The Dow Jones is up over 150 points while the S&P 500 is up 0.84%. Among the stocks traders are watching include Apple Inc. (NASDAQ:AAPL), Biogen Inc. (NASDAQ:BIIB), Amgen, Inc. (NASDAQ:AMGN), Deckers Outdoor Corp (NASDAQ:DECK), and Diamondback Energy Inc (NASDAQ:FANG). Let's analyze why each stock is […]
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN ) KRAS G12C inhibitor abstract showed promising ...
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...